文献速递流行病学与生物统计临床试验与 GCP

单价COVID-19 mRNA疫苗在80万青少年中的安全性和有效性及奥密克戎变异株所致住院的危险因素:瑞典全国队列研究

Safety and effectiveness of monovalent COVID-19 mRNA vaccination and risk factors for hospitalisation caused by the omicron variant in 0.8 million adolescents: A nationwide cohort study in Sweden.
PubMed 文献 · PLoS Med · 2023-02-21

接种与全因住院风险降低16%相关,两剂疫苗对COVID-19住院的有效性为76%,既往感染和脑性瘫痪/发育障碍是主要危险因素。

要点

  • 接种单价mRNA疫苗与全因住院风险降低16%相关(95%CI 12-19)。
  • 两剂疫苗接种对奥密克戎期COVID-19住院的有效性为76%(95%CI 57-87)。
  • 既往感染和脑性瘫痪/发育障碍是COVID-19住院的主要危险因素。

核心结论

  • 单价COVID-19 mRNA疫苗接种未增加导致住院的严重不良事件风险。
  • 两剂疫苗接种与奥密克戎流行期COVID-19住院风险降低相关,在有特定易感条件的青少年中亦然,该人群应优先接种。
  • 青少年普通人群中COVID-19住院极为罕见,此阶段可能不需要额外剂次。

研究设计与样本

  • 全国性队列研究,使用瑞典全国登记数据。
  • 安全性分析纳入2003年至2009年出生(11.3至19.2岁)至少接种1剂单价mRNA疫苗者645,355人及从未接种对照186,918人。
  • 疫苗有效性分析纳入接种2剂单价mRNA疫苗者501,945人及从未接种对照157,979人,随访至多5个月,奥密克戎流行期(2022年1月1日至2022年6月5日)。
  • 分析校正年龄、性别、基线日期及是否在瑞典出生。

主要发现

  • 安全性分析显示接种与全因住院风险降低16%相关(95%CI 12-19,p<0.001),30种选定诊断在组间仅有边际差异。
  • 疫苗有效性分析中,两剂接种者COVID-19住院21例(0.004%),对照26例(0.016%),疫苗有效性76%(95%CI 57-87,p<0.001)。
  • COVID-19住院的主要危险因素包括既往感染(细菌感染、扁桃体炎和肺炎)(OR 14.3,95%CI 7.7-26.6,p<0.001)和脑性瘫痪/发育障碍(OR 12.7,95%CI 6.8-23.8,p<0.001),这些亚组的疫苗有效性估计与总队列相似。
  • 两剂接种预防1例COVID-19住院的需接种人数在总队列为8,147,在既往感染或发育障碍者为1,007。
  • 因COVID-19住院的个体在30天内无死亡。

临床怎么用

  • 作者指出,有特定易感条件(既往感染、脑性瘫痪/发育障碍)的青少年应优先接种疫苗。
  • 作者认为,青少年普通人群中COVID-19住院极为罕见,此阶段可能不需要额外剂次。

局限性

  • 观察性设计。
  • 可能存在未测量的混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Real-world evidence on the safety and effectiveness of Coronavirus Disease 2019 (COVID-19) vaccination against severe disease caused by the omicron variant among adolescents is sparse. In addition, evidence on risk factors for severe COVID-19 disease, and whether vaccination is similarly effective in such risk groups, is unclear. The aim of the present study was therefore to examine the safety and effectiveness of monovalent COVID-19 mRNA vaccination against COVID-19 hospitalisation, and risk factors for COVID-19 hospitalisation in adolescents. METHODS AND FINDINGS: A cohort study was conducted using Swedish nationwide registers. The safety analysis included all individuals in Sweden born between 2003 and 2009 (aged 11.3 to 19.2 years) given at least 1 dose of monovalent mRNA vaccine (N = 645,355), and never vaccinated controls (N = 186,918). The outcomes included all-cause hospitalisation and 30 selected diagnoses until 5 June 2022. The vaccine effectiveness (VE) against COVID-19 hospitalisation, and risk factors for hospitalisation, were evaluated in adolescents given 2 doses of monovalent mRNA vaccine (N = 501,945), as compared to never vaccinated controls (N = 157,979), for up to 5 months follow-up during an omicron predominant period (1 January 2022 to 5 June 2022). Analyses were adjusted for age, sex, baseline date, and whether the individual was born in Sweden. The safety analysis showed that vaccination was associated with 16% lower (95% confidence interval (CI) [12, 19], p < 0.001) risk of all-cause hospitalisation, and with marginal differences between the groups regarding the 30 selected diagnoses. In the VE analysis, there were 21 cases (0.004%) of COVID-19 hospitalisation among 2-dose recipients and 26 cases (0.016%) among controls, resulting in a VE of 76% (95% CI [57, 87], p < 0.001). Predominant risk factors for COVID-19 hospitalisation included previous infections (bacterial infection, tonsillitis, and pneumonia) (odds ratio [OR]: 14.3, 95% CI [7.7, 26.6], p < 0.001), and cerebral palsy/development disorders (OR: 12.7, 95% CI [6.8, 23.8], p < 0.001), with similar estimates of VE in these subgroups as in the total cohort. The number needed to vaccinate with 2 doses to prevent 1 case of COVID-19 hospitalisation was 8,147 in the total cohort and 1,007 in those with previous infections or developmental disorders. None of the individuals hospitalised due to COVID-19 died within 30 days. Limitations of this study include the observational design and the possibility of unmeasured confounding. CONCLUSIONS: In this nationwide study of Swedish adolescents, monovalent COVID-19 mRNA vaccination was not associated with an increased risk of any serious adverse events resulting in hospitalisation. Vaccination with 2 doses was associated with a lower risk of COVID-19 hospitalisation during an omicron predominant period, also among those with certain predisposing conditions who should be prioritised for vaccination. However, COVID-19 hospitalisation in the general population of adolescents was extremely rare, and additional doses in this population may not be warranted at this stage.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Nordström P, Ballin M, Nordström A, et al. Safety and effectiveness of monovalent COVID-19 mRNA vaccination and risk factors for hospitalisation caused by the omicron variant in 0.8 million adolescents: A nationwide cohort study in Sweden. PLoS Med. 2023. PMID: 36802397. doi:10.1371/journal.pmed.1004127

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。